Thursday, 22 September 2022
A diagnostic test, developed by experts at the University of Nottingham, will speed up the diagnosis of colorectal cancer in patients ensuring they receive treatment more effectively, potentially saving thousands of lives.
Based on research developed by scientists at the University, an IP license has been translated by a start-up company called PathGen Diagnostik Teknologi in collaboration with Bio Farma, to develop an affordable molecular diagnostic kit for patients with colorectal cancer (CRC) in Indonesia, called BioColoMelt-Dx.
Every year, more than 35,000 cases of CRC occur in Indonesia. Around 35% of CRC are in patients younger than 50. They have a poorer outcome, and many cases may be inherited. Management of CRC is by surgery, but up to 50% will also require chemotherapy. Precision treatment in these cases is vital to improve survival rates.
Dr Susanti Susanti and Professor Mohammad Ilyas from the School of Medicine at the University of Nottingham established the Nottingham-Indonesia Collaboration for Clinical Research and Training (NICCRAT) in 2019, with the aim of developing research partnerships with several Indonesian research institutions.
This new test is the result of this research. It is cheap and easy to use and will potentially save thousands of lives, as it allows more precise and effective treatment of CRC, while preventing the side-effects of unnecessary treatment. It will also determine if the patients have inherited Lynch Syndrome (LS).
LS is a hereditary type of CRC that is associated with a younger age of patients with CRC. Detecting LS has been long reported to be a cost-effective strategy to provide aid in the diagnosis or management of the individual or at-risk family members by implementing appropriate surveillance for early diagnosis of associated cancers.
The test will now allow the families of patients who may share the same genetic condition to be monitored earlier, to detect and potentially prevent the cancer.
The Indonesia Minister of Health, Mr. Budi Gunadi Sadikin, officially launched the test in the summer at an event attended by Mr. Rob Fenn, the Deputy Head of Mission to Indonesia and Timor Leste. It is now being rolled out in some of Indonesia’s largest hospitals in including the National Cancer Centre.
Professor Mohammad Ilyas said: “I am extremely proud and excited to see our lab work being translated into a product which will impact on peoples’ lives – prolonging some and preventing others from receiving inappropriate therapy. I am grateful for the support from our funders – British Council’s Newton Fund – and our collaborators in Indonesia. Without them, our data would have remained as a piece of interesting lab work.”
More information is available from Dr Susanti Susanti in the School of Medicine at firstname.lastname@example.org
Notes to editors:
The University of Nottingham
Our academics can now be interviewed for broadcast via our Media Hub, which offers a Quicklink fixed camera and ISDN line facilities at Jubilee campus. For further information please contact a member of the Press Office on +44 (0)115 951 5798, email email@example.com
For up to the minute media alerts, follow us on Twitter
The University of Nottingham is a research-intensive university with a proud heritage. Studying at the University of Nottingham is a life-changing experience, and we pride ourselves on unlocking the potential of our students. We have a pioneering spirit, expressed in the vision of our founder Sir Jesse Boot, which has seen us lead the way in establishing campuses in China and Malaysia - part of a globally connected network of education, research and industrial engagement. Ranked 18th in the UK by the QS World University Rankings 2023, the University’s state-of-the-art facilities and inclusive and disability sport provision is reflected in its crowning as The Times and Sunday Times Good University Guide Sports University of the Year twice in three years, most recently in 2021. We are ranked seventh for research power in the UK according to REF 2021. We have six beacons of research excellence helping to transform lives and change the world; we are also a major employer and industry partner - locally and globally. Alongside Nottingham Trent University, we lead the Universities for Nottingham initiative, a pioneering collaboration which brings together the combined strength and civic missions of Nottingham’s two world-class universities and is working with local communities and partners to aid recovery and renewal following the COVID-19 pandemic.